This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaklamani, V. G. Articles by Mantzoros, C. Search for Related Content PubMed PubMed Citation Articles by Kaklamani, V. G. Articles by Mantzoros, C.

Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk

¹ Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University; ² Department of Health Studies, Medicine and Human Genetics, University of Chicago, Chicago, Illinois; ³ Division of Endocrinology and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; ⁴ Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center; and ⁵ Human Genetics Program, Department of Pediatrics, New York University Medical Center, New York, New York

Requests for reprints: Boris Pasche, Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 676 North St. Clair Street, Suite 880 Chicago, IL 60611. Phone: 312-695-0320; Fax: 312-695-0318; E-mail: b-pasche{at}northwestern.edu.

Key Words: adiponectin • breast cancer risk • variants

Breast cancer risk is higher among obese women and women with diabetes. Adiponectin is a protein exclusively secreted by adipose tissue, circulating levels of which have been associated with breast cancer risk. Whether genetic variants within the adiponectin pathway are associated with breast cancer risk is unknown. To explore the association of genetic variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes with breast cancer risk, we conducted a case control study of female patients with breast cancer and healthy female controls from New York City recruited between 1999 and 2004. We genotyped 733 hospital-based breast cancer cases and 839 controls for 10 haplotype-tagging single nucleotide polymorphisms (SNP) of ADIPOQ and ADIPOR1. Two ADIPOQ SNPs (rs2241766 and rs1501299), which have been associated with circulating levels of adiponectin, were associated with breast cancer risk [rs1501299*GG: odd ratios (OR), 1.80; 95% confidence interval (95% CI), 1.14–2.85; rs2241766*TG: OR, 0.61; 95% CI, 0.46–0.80]. One ADIPOR1 SNP (rs7539542), which modulates expression of adiponectin receptor 1 mRNA, was also associated with breast cancer risk (OR, 0.51; 95% CI, 0.28–0.92). Based on the known function of rs2241766 and rs1501299, we categorized individuals by adiponectin signaling status and found that, when compared with high signalers, intermediate signalers had a 4.16-fold increase in breast cancer risk (95% CI, 0.49–35.19), and low signalers had a 6.56-fold increase in breast cancer risk (95% CI, 0.78–54.89; P_trend = 0.001). This is the first report of an association between functionally relevant variants of the adiponectin pathway and breast cancer risk. The results warrant further studies of the adiponectin pathway in breast cancer. [Cancer Res 2008;68(9):3178–83]

This article has been cited by other articles:

				L. R. Teras, M. Goodman, A. V. Patel, M. Bouzyk, W. Tang, W. R. Diver, and H. S. Feigelson No Association between Polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and Postmenopausal Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2553 - 2557. [Abstract] [Full Text] [PDF]

				V. G. Kaklamani, K. B. Wisinski, M. Sadim, C. Gulden, A. Do, K. Offit, J. A. Baron, H. Ahsan, C. Mantzoros, and B. Pasche Variants of the Adiponectin (ADIPOQ) and Adiponectin Receptor 1 (ADIPOR1) Genes and Colorectal Cancer Risk JAMA, October 1, 2008; 300(13): 1523 - 1531. [Abstract] [Full Text] [PDF]